Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 17th International Conference on Cancer Research Barcelona, Spain.

Day 1 :

Keynote Forum

Eleni Petsalaki

University of Crete, Greece

Keynote: Chk1 is required for optimal spindle formation

Time : 10:00-10:30

Cancer-Research-2020 International Conference Keynote Speaker Eleni Petsalaki photo

Eleni Petsalaki has completed her PhD at the age of 28 years at the University of Crete. She is currently a post doctoral research scientist in Dr George Zachos’ Cell Cycle and Division Lab at the University of Crete where she is investigating mechanisms of mitotic cell division in human cells. She has published 8 papers in peer reviewed journals including Nature Communications, Journal of Cell Biology, Journal of Cell Science and others, 2 review articles and 2 commentaries.



The mitotic spindle consists mainly of microtubules (MTs) and is essential for accurate distribution of chromosomes in the two daughter cells during cell division. Errors in spindle formation can lead to incorrect separation of chromosomes or unequal size of daughter cells, which are associated with carcinogenesis or developmental disorders. However, the molecular mechanisms of spindle formation are not fully understood. In the present study, we show for the first time that Chk1, a kinase involved in the cellular response to DNA damage, is essential for optimal density and effective polymerisation of the spindle MTs in human cells. Chk1 localises to the centrosomes (the main centers of MTs organization) in mitosis and phosphorylates β-tubulin in newly identified sites in vitro. Also, reduced microtubule density in cells without functional Chk1 is associated with formation of disorganized spindles. We suggest that Chk1 phosphorylates β-tubulin to promote optimal spindle MT polymerisation. These findings describe novel mechanisms that could protect against carcinogenesis and developmental disorders, through regulating formation of the mitotic spindle


Eleni Petsalaki has completed her PhD at the age of 28 years at the University of Crete. She is currently a post doctoral research scientist in Dr George Zachos’ Cell Cycle and Division Lab at the University of Crete where she is investigating mechanisms of mitotic cell division in human cells. She has published 8 papers in peer reviewed journals including Nature Communications, Journal of Cell Biology, Journal of Cell Science and others, 2 review articles and 2 commentaries.

Speaker Publications:

1. “Building bridges between chromosomes: novel insights into the abscission checkpoint”, July 2019Cellular and Molecular Life Sciences, CMLS 76(21), DOI: 10.1007/s00018-019-03224-z

2. “Chmp4c is required for stable kinetochore-microtubule attachments”, Chromosoma 127(4), DOI: 10.1007/s00412-018-0675-8

3. “Src activation by Chk1 promotes actin patch formation and prevents chromatin bridge breakage in cytokinesis”, The Journal of Cell Biology 217(9):jcb.201802102, DOI: 10.1083/jcb.201802102

4. “Novel ESCRT functions at kinetochores”, Aging 10(3), DOI: 10.18632/aging.101399

Keynote Forum

Jenea Bintey Khan

National Institute of Cancer Research & Hospital (NICRH), Dhaka, Bangladesh

Keynote: Small Commissioning of a Flattening Filter Free (FFF) using an Anisotropic Analytical Algorithm (AAA)
Cancer-Research-2020 International Conference Keynote Speaker Jenea Bintey Khan photo

Jenea Bintey Khan is a Bio-medical engineer and recently she is working on National Institute of Cancer Research & Hospital, Mohakhali, Dhaka, Bangladesh in the department of radiotherapy and have recently focus on the article on Commissioning of a Flattening Filter Free (FFF) using an anisotropic analytical algorithm.



Aim: To compare the dosimetric parameters of the flattened and flattening filter free (FFF) beam and to validate the beam data using anisotropic analytical algorithm (AAA).

Materials and Methods:  All the dosimetric data’s (i.e. depth dose profiles, profile curves, output factors, penumbra etc.) required for the beam modeling of AAA were acquired using the Blue Phantom RFA for 6MV, 6FFF, 10MV & 10FFF. Progressive resolution Optimizer and Dose Volume Optimizer algorithm for VMAT and IMRT were are also configured in the beam model. Beam modeling of the AAA were compared with the measured datasets.

Results: Due to the higher and lover energy component in 6FFF and 10FFF the surface doses are 10 to 12% higher compared to flattened 6MV and 10MV beams. FFF beam has a lower mean energy compared to the flattened beam and the beam quality index were 6MV 0.667, 6FFF 0.629, 10MV 0.74 and 10FFF 0.695 respectively. Gamma evaluation with +2% dose and 2mm distance criteria for the Open Beam, IMRT and VMAT plans were also performed and found a good agreement between the modeled and measured data.

Conclusion: We have successfully modeled the AAA algorithm for the flattened and FFF beams and achieved a good agreement with the calculated and measured value

Keynote Forum

Mazarieb Mai

Rabin Medical Center, Israel

Keynote: Post-surgical Colorectal Cancer (CRC) surveillance: PET/CT versus CT
Cancer-Research-2020 International Conference Keynote Speaker Mazarieb Mai photo

Mai Mazarieb is a MD at Department of General Surgery, Rabin Medical Center, Zarzir, Israel. Her study focused on entitled post-surgical Colorectal Cancer (CRC) surveillance: PET/CT versus CT. Her research interest focus on cancer, surgery


Introduction:  Forty percent of CRC patients will fail, mostly within first two years following primary resection. Early detection of recurrent disease has been reported to improve their survival. The use of PET/CT during the follow-up process is equivocally superior to contrast enhanced CT. This study is a comparison of CT vs. PET/CT.

Methods: Medical records of all patients who had R0 radical colorectal surgery for Stage 1-3 disease between 1.2000 and 1.2016 were retrospectively reviewed. All patient who experienced recurrence and had both abdominal and/or chest CT scans followed by PET/CT within 60 days, were included in the study. A radiologist reviewed all images for disease recurrence. Findings consistent with recurrent disease were compared between the two modalities.

Results: Of 35 CT images 14 identified lung nodules; 10 of these 14 were confirmed malignant by FDG uptake. .9 CT images identified liver lesions, all were called “cystic”; PET/CT identified 10 liver cases; 6 of these 10 cases were called disease recurrence to the liver. One case was not demonstrated by CT while PET/CT did identify a disease recurrence in the liver. CT and PET/ CT both identified 7 peritoneal cases, but only 3 cases; were FDG avid (see table). PET/CT identified all anastomotic recurrences (N=4), these were noted only 3 times on CT.

Conclusions: A notable proportion of patients with negative findings on routine CT performed presented with a positive PET/CT. PET/CT should be employed in the follow-up protocol and replaced the CT.

Speaker Publications:

  1. “Melanoma Seeding at the Chest-Wall Port Site Following the Thoracoscopic Removal of a Right Lower Lobe Metastasis”, Annals of Surgical Case Reports, Volume 3, Issue 1, Article 1026, Published: 17 Feb, 2020
  2. Outaggarts Z, Johnstone S, Goodman A. Port-site metastasis after laparoscopic surgery with rapid second recurrence in early stage endometrial carcinoma: A case report and review of the literature. Open J Obstet Gynecol. 2015;5(6):324-32
  3. Emoto S, Ishigami H, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, et al. Port-site metastasis after laparoscopic surgery for gastrointestinal cancer. Surg Today. 2017;47(3):280-3.


Keynote Forum

Mingzhu Yin

Xiangya Hospital, Central South University, China

Keynote: Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

Time : 17:00-17:20

Cancer-Research-2020 International Conference Keynote Speaker Mingzhu Yin photo

Mingzhu Yin has completed his MD at the age of 25 years from Harbin Medical University and postdoctoral studies from Yale University School of Medicine. He is the co-director of Dermatology Department at the Xiangya Hospital. He has published more than 40 papers in reputed journals and has been serving as an editorial board member of repute.


Efficient and controlled delivery of nucleic acids by viral and synthetic carriers with low toxicity is one of the most important challenges facing the gene therapy. Non-viral vectors are perfect candidates for this goal because the use of viral vectors has a high risk of inducing unwanted immune responses. For medical applications, a use of nanostructured polymers every year brings more and more possibilities. The creation of new polymers and the study of their biocompatibility is very important to find better and safer vectors for gene therapy. In this work we compared conventional transfection and deposition transfection performed with the use of cationic star polymer. Obtained polyplexes were tested for cytotoxicity and luciferase activity using HT-1080 cells as a model. One of the solutions to increase transfection efficiency seems to be the deposition of the nucleic acid itself or its polyplex on solid support. The support used for the purpose is functioning as a substrate supporting the organization and differentiation of cells, while immobilized DNA or RNA delivers significant genetic information into the cells. The major advantages of the immobilization of nucleic acid/polyplexes include the direct contact of polymer layer loaded with the nucleic acid with the cells during the proliferation. The performed studies demonstrated that we obtained the novel effective system, based upon star polymer architecture, which is potentially useful for gene delivery. This work was supported by the Polish National Science Center contract no. UMO-2015/17/B/ST5/01095

Speaker publications:

  1. “Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling”, Journal of proteome research, 2013/1/4, 505-512
  2. “Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer”, The Journal of clinical investigation 126 (11), 4157-4173
  3. “Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry”, Clinica Chimica Acta 413 (9-10), 861-868
  4. “The Long-Term Efficacy of Neoadjuvant Chemotherapy Followed by Radical Hysterectomy Compared With Radical Surgery Alone or Concurrent Chemoradiotherapy on Locally Advanced-Stage Cervical Cancer”, International Journal of Gynecologic Cancer 21 (1),

Cancer-Research-2020 International Conference Keynote Speaker Muhammad Usman  photo

Muhammad Usman, a former Director General of Agricultural Research System, Government of Pakistan who retired from service after a spotless career of about 32 years with senior level experience on research and development of integrated agricultural production, industries, Agriculture & Horticulture and bioenergy on a sustainable way



The aim of presentation consist of oncology, Cancer Science, therapy, health different types of cancer were studied and reported that Oncology Cancer Science and Therapy is the major tools for the development health as well as to control the different types of cancer diseases in the world.   The study reported that the world oncology consist of two parts i.e “onco” means bulk, mass, or tumor while “logy” means study. Therefore oncology is known is the study of tumors or different type of cancer diseases. In other words, oncology is the branch of science that deals with the tumor and cancer diseases. The study also reported that oncology is the study of cancer and it treatment in medical science. The study further reported that cancer is a group more than 100 different disease. Cancer is very serious disease as it can developed almost anywhere in the body. The most important oncology diagnostic remains the clinical history of the patient. Common symptoms that point towards cancer include fatigue, weight loss, unexplained anemia, fever of unknown origin etc. Oncology depends on diagnostic tools like biopsy or removal of bits of the tumors tissue and examining it under the microscope. Other diagnostic tools include endoscopy for the gastrointestinal tract, imaging studies like X-rays, CT scanning, MRI scanning, ultrasound and other radiological techniques, Scintigraphy, Single Photon Emission Computed Tomography, Positron emission tomography and nuclear medicine techniques etc. The oncologist’s role including explaining the cancer diagnosis and stage to the patient. Discussing all the relevant treatment options and the oncologist’s recommendations. In other words Cancer Science a disease caused by an uncontrolled division of abnormal cells in a part of the body. Further reported that a malignant growth or tumor resulting from an uncontrolled division of cells. Similarly Cancer therapy describes the treatment of cancer in a patient, often with surgery, chemotherapy and/or radiotherapy. Targeted therapies are also available for some cancer types.

The study reported that the total countries available in the world are 225, consist of (Developed countries = 49, developing countries = 150, observer state = 4, state without partial recognition = 8, unrecognized state = 14). Similarly, South Asia comprises the countries of Pakistan, Bangladesh, India, Bhutan, Maldives, Nepal and Sri Lanka.  In the light of above study, it is proposed that Cancer Science and Therapy should be commercialized  for the development of health, basic need of daily life, create employment, generate income, stronger economy, reducing financial crises, global Poverty and hunger in the developing countries of the world particularly in south Asia

Speaker Publications

  1. Food and Beverages are the major industries for the improvement of health, daily use of life, reduction in financial crises, poverty and hunger in the world

Cancer-Research-2020 International Conference Keynote Speaker Zeynep-Elif Apaydın  photo

Zeynep Elif Apaydın was born in 1993 in Samsun, Turkey. When she was a student in high school, she decided to study molecular biology and genetics. She has started to study in T.C. İstanbul Kültür University and moved to İstanbul in 2012. She currently pursues a master's degree at İstanbul Kültür University and continues her studies on cancer research. She has given 2 poster presentations in international congresses related to her research. She is planning to continue her work on academical field after graduation from master's programme



Growth Hormone Releasing Hormone (GHRH), 44 amino acid containing hypothalamic hormone, retained its biological activity by first 29 amino acids

1. GHRH (NH2 1-29) peptide antagonists inhibits growth of prostate, breast, ovarian, renal, gastric, pancreatic cancer in vitro and in vivo

2. Aptamers, single-strand RNA or DNA oligonucleotides are capable of binding against target molecules with high affinity

3. Our aim in this study is to synthesize and select aptamers against GHRH (1-29) peptide and demonstrate synthesized aptamers’ inhibitive effect on PC3, HT29 and MIA PaCa-2 cells. Aptamers against GHRH (NH2 1-29) peptides were synthesized by X-aptamer selection kit after biotinylating of target protein. Binding affinity (Kd) of GHRH (NH2 1-29) X-aptamers were determined by dot-blot method. Binding of aptamers against GHRH and its receptor and blocking of GHRH signaling was determined by GH, GHRH-R immunofluorescence assay. Dose- and time-dependent effect of X-aptamers on cell viability, mitochondrial membrane potential, apoptotic effects on PC3, HT29, MIA PaCa-2 cells were determined by MTT cell viability assay, DiOC6, DAPI, PI staining, and Annexin V/PI.

FACS flow analysis, respectively. Binding affinity of two of five putative GHRH (1-29) X-aptamers were by 1.8-fold, TKY.T2.08 and TKY.T2.09 X-aptamers have significant suppression on GH, GHRHR expression without any alteration in intracellular Ca+2 and cAMP levels in HT29, MIA PaCa-2 cells. 500 nM TKY.T2.08/TKY.T2.09 X-aptamer decreased cell viability loss by 16/22 %, 41/20%, 22/10% in PC3, HT29 and MIA PaCa-2 cells for 72 h, respectively. TKY.T2.08/ TKY.T2.09 Xaptamer induced subG1 population accumulation by 5.4/4.5%, 3.7/4.7%, 24/14.7% in PC3, HT29 and MIA PaCa-2 cells for 72 h, respectively. In conclusion, two selected GHRH (1-29) X-aptamer triggered cell viability loss and induced apoptotic cell death in PC3, HT29, MIA PaCa-2 cells via suppressing the expression of GH and GHRH-R. The project was funded by TUBİTAK-1001 National Scientific Research

Speaker Publications:

  1. M. R. Ehlers, “Recombinant human GHRH (1-44) NH 2: Clinical utility and therapeutic development program,” Endocrine, vol. 14, no. 1, pp. 137–141, 2001, doi: 10.1385/ENDO: 14:1:137.
  2. F. G. Rick et al., “Antagonists of growth hormone-releasing
  3. hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases,” Proc. Natl. Acad. Sci. U. S. A., vol. 109, no. 5, pp. 1655–1660, 2012, doi: 10.1073/pnas.1120588109.
  4. C. Walss-Bass et al., “X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia,” Mol. Neuropsychiatry, vol. 5, no. 1, pp. 52–59, 2019, doi: 10.1159/000492331.

Cancer-Research-2020 International Conference Keynote Speaker Subhasis Misra photo

Subhasis Misra, MD is a Surgical Oncology Specialist in Brandon, FL.  He is affiliated with medical facilities Brandon Regional Hospital and Northwest Texas Healthcare System.  He is accepting new patients and has indicated that he accepts telehealth appointments



Introduction: Parathyroid cancer (PC) is an extremely uncommon malignancy with a frequency of 0.005% of all the malignancies and also contributes almost 0.74%-4.7% of all the hyperparathyroidism. Most of the manifestations of the PC are mainly secondary to its complications, including hypercalcemia, nephrolithiasis, peptic ulcer disease (PUD), and bone pathologies. Most of the data related to this rare disease is limited to case series and very few database studies. To the best of our knowledge, we present the largest database study which aims to investigate the demographic, clinical, and pathological factors impacting prognosis and survival of PC.

Methods: Demographic and clinical data of 609 patients with PC was abstracted from the Surveillance Epidemiology and End Result (SEER) database (1975 – 2016). Chi-square test, paired t-test, and cox regression multivariate analysis was used to analyze the data.

Results: The PC had a higher incidence amongst males (52.2%, p<0.005), Caucasians (75.4%, p<0.005), and had a mean age of diagnosis 62±10 years. When grading information was reported, most of the PC was the well-differentiated tumors (Grade 1) (9.3 %) and had Adenocarcinoma NOS histological type (99.7%), p=<0.005. When reported, most of PC were 2-4cm cm in size (56.6 %) and were localized to the gland (65.5 %), p=<0.001. Lymph nodes were only positive in 2.3 % of the entire cohort. Most PC patients were treated surgically (97.2%), followed by the radiation alone (12%), and very few patients received chemotherapy (0.9 %). The 5-year overall observed survival for PC was 82.7 %, while those who underwent surgery only and radiation alone had a 5- year survival of  83.8 %, and 72.2 %, respectively, P=0.037. Multivariate analysis identified age, gender, distant spread, and poorly differentiated histology poorly differentiated grade to be independently associated with increased mortality for PC, p<0.001.

Conclusion: PC is a rare tumor that mostly affects patients in their 6th decade and primarily affects men and Caucasians. Surgical resection offers the optimal survival advantage, while the radiation alone or in combination with surgery does not provide added survival benefits. To understand better the pathogenesis and factors impacting the survival, all patients diagnosed with PC should be enrolled in a large-scale to the national and international registries.


Keynote Forum

Sang Youn Hwang

Dongnam Institute of Radiological & Medical Sciences, Korea

Keynote: Efficacy of cabozantinib as third or fourth line therapy in patients with advanced hepatocellular carcinoma
Cancer-Research-2020 International Conference Keynote Speaker Sang Youn Hwang photo


Sang Youn Hwang is currently affiliated to the Department of Internal Medicine and Gastrointestinal Cancer Centre in Dongnam Institute of Radiological & Medical Sciences, Republic of Korea


Background: Cabozantinib is approved as second line therapy in patients with progression after sorafenib in hepatocellular carcinoma (HCC) patients, however the study about efficacy of cabozantinib as third or fourth line therapy (esp. in the case of progression after nivolumab). We aimed to evaluate the efficacy and safety of cabozantinib as 3rd & 4th line treatment in patients with advanced HCC with progressive disease after TKI and nivolumab.

Methods: Eligible advanced HCC patients with documented radiological evidence of disease progression with previous 1st & 2nd line systemic treatment were recruited in our hospital from Mar 2019 to Aug 2019. All patients initially received cabozantinib 60mg daily as fixed starting dose every 4 weeks for unlimited cycles untile radiologic progression.

Results:  Six patients (3rd line Tx in one patient, 4th line Tx in five patients) were enrolled in the study. All five patients previously received three sequential therapies (sorafenib → regorafenib → nivolumab) and only one patient received two sequential therapies (sorafenib → nivolumab). The median level of AFP was 128.6 ng/mL (1.3-20948), that of PIVKA was 2131 mAU/Ml (1057-29440) in 2L group. The median OS was 5 months (range 3-6.5) and the median PFS was 4 months (range 3-6.5). The OS and in sorafenib responder & non responder were not different significantly (median OS 4 vs 3 months; p-value=0.503). All patient achieved stable disease. Grade 3 or 4 adverse events occurred in 3 patients (66.6%). The most common high-grade events fatigue (50%) and diarrhea (16%). Interruption of drug was happened in all patients within 8 weeks and dose reduction was occurred in 4 patients (66.6%).

Conclusions: Our study suggests that cabozantinib can be relatively effective and safe strategy as 3rd and 4th line therapy in HCC patients refractory for previous systemic therapy. A further well controlled, large scaled study to prove survival benefit is recommended.

Speaker affiliations:

  1. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea, Investigational New Drugs, DOI: 10.1007/s10637-020-00977-4
  2. Effect of Urea Cream on Sorafenib-Associated Hand-Foot Skin Reaction in Patients with Hepatocellular Carcinoma: A Multicenter, Randomized, Double-Blind Controlled Study, SSRN Electronic Journal, DOI: 10.2139/ssrn.3543611
  3. A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy, Journal of Liver Cancer 19(1):74-78, DOI: 10.17998/jlc.19.1.74


Keynote Forum

Shi-Jun Xu

National Henan Cancer Hospital, China

Keynote: Small MiRNAs, vital regulators in tumor immunity: With a focus on innate immunity
Cancer-Research-2020 International Conference Keynote Speaker Shi-Jun Xu photo

Shi-Jun Xu has completed her PhD at the age of 30 years from Sun Yat-sen University. She is the key member of Cancer Research Group in Radiology Department, National First-level Disciplines in Henan Cancer Hospital. She has published 3 papers in reputed journals.


 The tumor microenvironment (TME) is the primary arena where tumor cells and the host immune system interact. Bidirectional communication between tumor cells and the associated stromal cell types within the TME influences disease initiation and progression, as well as tumor immunity. There are multiple types of stromal cells and among them, macrophages and natural killer (NK) cells are the most prevalent. They not only are key players in innate immunity which serves as the first barrier against pathogen infection and as the bridge to connect adaptive immunity, but also play important roles in tumor immunity. Besides, epithelial cells, such as hepatocytes in liver, perform robust innate immune response against pathogen infection and tumor initiation. More importantly, these cells display either pro- or anti-tumor properties, depending on the expression of key regulators. MicroRNAs (miRNAs) are emerging as such regulators. They affect not only immune cells but also epithelial cells whose functions closely related to pathogen infection, tumor initiation and tumor evasion of the immune system. In this review we will discuss the role of miRNAs in tumor immunity, focusing particularly on innate immunity related cells such as macrophages, NK cells and hepatocytes.


Cancer-Research-2020 International Conference Keynote Speaker Zhan-Qiang Jin photo


Zhan-Qiang Jin has completed his MD at the age of 35 years from Capital Medical University. He is the director of Ultrasound Department of Guilin Medical University. He has published more than 30 papers in reputed journals and has been serving as an editorial board member




The study developed a modified TI-RADS score using gray-scale ultrasound, contrast-enhanced ultrasound (CEUS), and shear-wave elastography (SWE) images to predict malignancy of thyroid nodules and compared this modified score system with the subjective scoring criteria based on ACR TI-RADS (2017 edition). By using SWE and CEUS (enhanced pattern) to downgrade TI-RADS category 4 and 5 nodules, the malignancy rate for TI-RADS category 4 and 5 nodules increased from 47.6% with ACR TI-RADS assessment alone to 49.4% with ACR TI-RADS combined SWE and CEUS (enhanced pattern). Likewise, by using the modified TI-RADS to adjust TI-RADS category 3 nodules, the malignancy rate for TI-RADS category 3 nodules increased from 13.9% to 20.0%. Interestingly, applying the modified TI-RADS to adjust TI-RADS category 4 or 5 nodules, the malignancy rate for TI-RADS category 4 or 5 nodules decreased from 31.0% or 75.4% with ACR TI-RADS assessment alone to 27.8%  or 72.9% with ACR TI-RADS combined SWE and CEUS (enhanced pattern). The discriminating power for detection of malignancy of the variable score 2, with an AUC of 0.899 (95% CI, 86.1%-93.6%), was higher than that of score 1, with an AUC of 0.862 (95% CI, 81.9%-90.6%; P > 0.05). With a point 4.5 as the optimal cutoff value, a score of 1 (ACR TI-RADS) predicted malignancy with an accuracy of 75.6%, sensitivity of 85.0%, and specificity of 71.6%. However, with a point 5.5 as the optimal cutoff value, a score of 2 (ACR TI-RADS + SWV + CEUS) predicted malignancy with an accuracy of 84.9%, sensitivity of 81.0%, and specificity of 86.6%. The modified TI-RADS based on ACR TI-RADS + SWE + CEUS (enhanced pattern) could contribute to reducing the number of biopsies performed on benign nodules and to implementing consistent follow-up in clinical practice.

 Speaker Publications:

1. “Clinical Study of the Prediction of Malignancy in Thyroid Nodules: Modified Score versus 2017 American College of Radiology's Thyroid Imaging Reporting and Data System Ultrasound Lexicon”, Ultrasound Med Biol 2019 07 4;45(7):1627-1637. Epub 2019 May,

2. “Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study”, BMC Cancer 2019 Apr 11;19(1):345. Epub 2019 Apr 11,

3. “Color Doppler Ultrasound in Diagnosis and Assessment of Carotid Body Tumors: Comparison with Computed Tomography Angiography”, June 2016, Ultrasound in medicine & biology 42, DOI: 10.1016/j.ultrasmedbio.2016.04.007

Keynote Forum

Alisa Morshneva

Institute of Cytology of Russian Academy

Keynote: The role of adenoviral E1A in HDACi-Dependent FoxO Regulation
Cancer-Research-2020 International Conference Keynote Speaker Alisa Morshneva photo

Alisa Morshneva completes her Master’s Biology program of Saint-Petersburg State University in 2020. She holds a Bachelor’s degree in Biology, Saint-Petersburg State University, 2018. In 2019 she has completed the one and half year program Bioinformatics for Biologists of Bioinformatics Institute, Saint-Petersburg. Since 2015, she has been working at Institute of Cytology of Russian Academy of Sciences  as a researcher.



The adenoviral early region 1A (E1A) protein is being actively studied in the context of cancer therapy due to its proapoptotic and angiogenic activity and its ability to cause chemosensitization. Previous studies demonstrate that E1A-induced chemosensitization can be mediated  by Forkhead box O (FoxO) transcription factors. Hence, we explored the relationship between E1A expression and the modulation of FoxO activity with histone deacetylase inhibitors (HDACi). Particularly, we found that the basal FoxO protein level is elevated in E1A-expressing cells and that prolonged treatment of E1A-expressing cells with HDACi sodium butyrate (NaBut) results in the suppression of the FoxO expression and activity. In contrast, in E1A-negative cells, NaBut increases the transactivation ability of FoxO over time. NaBut-induced decrease of FoxO activity in E1A-expressing cells can be driven by the NaBut-dependent decrease in E1A expression level. These facts suggest that NaBut-induced suppression of FoxO in E1A-positive cells can be mitigated by E1A overexpression. By exploring the possible causes of E1A-induced stabilization of FoxO we found that the CBP/p300-binding domain of E1Aad5 is involved in FoxO stabilization. Taken together, our results reveal that E1A expression increases FoxO stability but makes the level of FoxO decreased after HDACi treatment.


Keynote Forum

Eva Katona

University of Debrecen, Hungary

Keynote: Investigation of the circadian clock genes in human melanoma cells

Time : 09:40-10:10

Cancer-Research-2020 International Conference Keynote Speaker Eva Katona photo

Eva Katona is graduated at the University of Debrecen in 2010, as medical biologist. She started her postgradual studies in the field of chondrogenic differentiation paralell with investigation of Ser/Thr phospatesis in human melanoma. In 2018, she started to studying the circadian clock of normal human epidermal pigment cells and melanoma cells, focusing on finding new strategies for resynchronization of the molecular clock of cancer cells.


Most of the cell functions show ~24 hour-periodic rhythm which is regulated by a 2-level endogenous rhythm-generator system. The clock machinery is composed of a central neural oscillator located in the brain, and peripheral clock systems found in different cells and tissues, where the expression of circadian clock genes is driven by a highly conserved transcription/translation feedback loop (TTFL).

It is hypothesised that cancer development and/or progression may correlate with the disruption of the circadian homeostasis of the cells. In case of melanoma, little is known about the elements, the function and the role of the biological clock. Recent studies suggest that re-synchronization of the circadian clock with special diet or pharmacological treatments may increase the positive effects of the antitumor therapies through decreasing cancer cell proliferation ability.

Based on the above, the aim of this research is to study the expression profile of the core molecular clock genes (BMAL1/2, CLOCK, CRY1/2, PER2/3, RevErba, RoRa) in WM35 melanoma cells and normal human epidermal melanocytes, as control cells. In addition to clock gene expression profiling, we show the alterations in the clock gene expression pattern upon re-synchronization with different methods i.e. serum shock or caloric restriction.

Our results suggest a differential regulation of the core molecular clock in melanoma cells compared to normal human epidermal melanocytes, which may have key implications in developing novel anti-cancer therapies.